Second CAR-T therapy for multiple myeloma approved; how often is breast cancer overdiagnosed?

The FDA's approval of cilta-cel could ease strain on limited supplies of potentially lifesaving cancer therapies. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

STAT+: FDA approves second CAR-T cancer therapy to treat multiple myeloma, opening the door for greater access By Angus Chen Adobe The FDA has approved a new CAR-T cancer therapy developed by Janssen and Legend Biotech to treat multiple myeloma. Read More How often is breast cancer overdiagnosed? New research finds true cases far outweigh false alarms By Angus Chen ANNE-CHRISTINE POUJOULAT/AFP via Getty Images Breast cancer clinicians say the study should reinforce the idea that the benefits of mammography generally outweigh its risks. Read More Opinion: A 'more, more, more' approach to cancer screening is misleading and harmful By David Ropeik Jim Cole/AP The harms of cancer screening — checking healthy people for hidden cancer — are often downplayed or ignored. They shouldn't be. Read More Sponsor content by STAT Events The STAT Breakthrough Science Summit On March 31, take an inside look at the technologies and procedures set to redefine medicine, and change patient care in the years to come. You'll hear from the CEOs, scientists, entrepreneurs at the forefront of these efforts. Get your pass now, and use your STAT+ subscriber login to unlock a 20% discount. STAT+: FDA asks Congress for more power to regulate certain diagnostic tests, including prenatal screenings By Nicholas Florko Jacquelyn Martin/AP The FDA wants clearer authority over certain diagnostic tests, including prenatal screenings for genetic issues. Read More Tuesday, March 1, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser